{"id":"dwp14012-a-mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL5314922","moleculeType":"Small molecule","molecularWeight":"436.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DPP-4 inhibitors work by blocking the enzyme that degrades glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their action. This leads to increased insulin secretion in response to meals and decreased glucagon secretion, resulting in improved glycemic control with a low hypoglycemia risk.","oneSentence":"DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:22.570Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06751121","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-02-06","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients, Helicobacter Pylori Infected Subjects","enrollment":461},{"nctId":"NCT06508645","phase":"PHASE1","title":"Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-01-10","conditions":"Healthy Volunteers","enrollment":33},{"nctId":"NCT04784910","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-05-21","conditions":"Peptic Ulcer","enrollment":423},{"nctId":"NCT06437951","phase":"PHASE1","title":"to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection","status":"NOT_YET_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-07","conditions":"Erosive Gastroesophageal Reflux Disease","enrollment":40},{"nctId":"NCT05868967","phase":"PHASE1","title":"A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-02-27","conditions":"Phase 1 Study, Healthy Volunteers","enrollment":8},{"nctId":"NCT05812404","phase":"PHASE1","title":"Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-10-26","conditions":"Drug Drug Interaction","enrollment":36},{"nctId":"NCT04341454","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-06-02","conditions":"Acute Gastritis, Chronic Gastritis","enrollment":327},{"nctId":"NCT04888819","phase":"NA","title":"Treatment Effect According to Timing of Administration of DWP14012 40 mg","status":"UNKNOWN","sponsor":"Konkuk University Medical Center","startDate":"2021-02-01","conditions":"Erosive Esophagitis","enrollment":186},{"nctId":"NCT04613895","phase":"NA","title":"Treatment Effect According to Timing of Administration of DWP14012 40 mg","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-11-17","conditions":"Erosive Esophagitis","enrollment":186},{"nctId":"NCT04341428","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-07-02","conditions":"Healed Erosive Esophagitis","enrollment":406},{"nctId":"NCT03487562","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2018-04-08","conditions":"Healthy","enrollment":48},{"nctId":"NCT03811080","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-02-07","conditions":"Non-Erosive Gastroesophageal Reflux Disease","enrollment":327}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DWP14012 A mg","genericName":"DWP14012 A mg","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}